Compare MDBH & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | MIRA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 43.7M |
| IPO Year | 2022 | 2023 |
| Metric | MDBH | MIRA |
|---|---|---|
| Price | $3.90 | $0.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 109.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $0.90 |
| 52 Week High | $5.50 | $2.45 |
| Indicator | MDBH | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 47.20 |
| Support Level | $3.08 | $0.99 |
| Resistance Level | $4.16 | $1.24 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 87.35 | 53.74 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.